Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE--To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population. DESIGN--Analysis of cost effectiveness based on the following assumptions: about 83,000 people have atrial fibrillation in Sweden, of whom 22,000 would be potential candidates for treatment with anticoagulants and 55,000 for aspirin treatment; the annual 5% stroke rate is reduced by 64% (with anticoagulants) and 25% (with aspirin); incidence of intracranial haemorrhage of 0.3%, 1.3%, or 2.0% per year; direct and indirect costs of a stroke of Kr180,000 and Kr90,000; estimated annual cost of treatment is Kr5030 for anticoagulants and Kr100 for aspirin. SETTING--Total Swedish population. MAIN OUTCOME MEASURES--Direct and indirect costs of stroke saved, number of strokes prevented, and cost of preventive treatment. RESULTS--Depending on the rate of haemorrhagic complications 34 to 83 patients would need to be treated annually with anticoagulants to prevent one stroke; 83 patients would need to be treated with aspirin. Giving anticoagulant treatment only would reduce costs by Kr60 million if the incidence of intracranial haemorrhage were 0.3% but would imply a net expense if the complication rate exceeded 1.3%. The total savings from giving anticoagulant (22,000 patients) and aspirin (55,000 patients) treatment would be Kr175 million per year corresponding to 2 million pounds per million inhabitants each year. CONCLUSIONS--Treatment with anticoagulants and, if contraindications exist, with aspirin is cost effective provided that the risk of serious haemorrhage complications due to anticoagulants is kept low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Cited by
Incidence of and risk factors for atrial fibrillation in older adults
Psaty, B. M., Manolio, T. A., Kuller, L. H., Kronmal, R. A., Cushman, M., Fried, L. P., White, R., Furberg, C. D., & Rautaharju, P. M. (1997) · Circulation · doi:10.1161/01.cir.96.7.2455 · Cited by 1,462
Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States
Coyne, K. S., Paramore, C., Grandy, S., Mercader, M., Reynolds, M., & Zimetbaum, P. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00124.x · Cited by 420
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community
Sudlow, M., Thomson, R., Thwaites, B., Rodgers, H., & Kenny, R. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01401-9 · Cited by 383
Hughes, M., Lip, G. Y. H., & on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-08-0508 · Cited by 371
Gage, B. F. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530230025025 · Cited by 329
Metadata
- Authors
- Gustafsson, C., Asplund, K., Britton, M., Norrving, B., Olsson, B., & Marké, L. A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1992-12-12
- Volume
- 305
- Issue
- 6867
- Pages
- 1457-1460
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2009519327
- Cited by
- 129
- References
- 1
- FWCI
- 9.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. https://app.cochat.ai/papers/10.1136/bmj.305.6867.1457
- The paper
- Gustafsson, C., Asplund, K., Britton, M., Norrving, B., Olsson, B., & Marké, L. A. (1992). Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. https://doi.org/10.1136/bmj.305.6867.1457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.